Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to $47.6 million.

  • Vanda Pharmaceuticals' Accounts Payables rose 2115.56% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 2115.56%. This contributed to the annual value of $39.1 million for FY2024, which is 162.77% up from last year.
  • Vanda Pharmaceuticals' Accounts Payables amounted to $47.6 million in Q3 2025, which was up 2115.56% from $57.1 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' Accounts Payables' 5-year high stood at $57.1 million during Q2 2025, with a 5-year trough of $26.1 million in Q1 2021.
  • Its 5-year average for Accounts Payables is $40.3 million, with a median of $39.1 million in 2024.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Accounts Payables surged by 9687.42% in 2022, and later tumbled by 3644.2% in 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Accounts Payables (Quarter) stood at $34.4 million in 2021, then surged by 32.27% to $45.6 million in 2022, then dropped by 15.57% to $38.5 million in 2023, then grew by 1.63% to $39.1 million in 2024, then rose by 21.83% to $47.6 million in 2025.
  • Its Accounts Payables stands at $47.6 million for Q3 2025, versus $57.1 million for Q2 2025 and $45.3 million for Q1 2025.